NCT03964207View on ClinicalTrials.gov

A Study on Whether Patients Prefer the Spiriva® Respimat® or the Spiriva® Handihaler® for Treating Their Chronic Obstructive Pulmonary Disease (COPD)

PHASE4CompletedINTERVENTIONAL
Enrollment

72

Participants

Timeline

Start Date

November 25, 2019

Primary Completion Date

October 19, 2021

Study Completion Date

November 16, 2021

Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
DRUG

Tiotropium Respimat® (T1)

inhalation solution

DRUG

Tiotropium Handihaler® (T2)

Inhalation Powder

Trial Locations (8)

100020

Beijing Chao-Yang Hospital, Beijing

100029

China-Japan Friendship Hospital, Beijing

110001

The First Hospital of China Medical University, Shenyang

200025

Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai

200032

Zhongshan Hospital Fudan University, Shanghai

510080

The First Afiliated Hospital, Sun Yet-sen University, Guangzhou

510120

First Affiliated Hospital of Guangzhou Medical University, Guangzhou

610041

West China Hospital, Chengdu

Sponsors
All Listed Sponsors
lead

Boehringer Ingelheim

INDUSTRY

NCT03964207 - A Study on Whether Patients Prefer the Spiriva® Respimat® or the Spiriva® Handihaler® for Treating Their Chronic Obstructive Pulmonary Disease (COPD) | Biotech Hunter | Biotech Hunter